Physician profile
Michael D Bernstein
NPI 1235368903
$7,074.02
in general payments reported to CMS, 2019-2025
14 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $222 · 2021: $357 · 2022: $476 · 2023: $2,947 · 2024: $1,719 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256 · Travel and Lodging: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.76 |
| Travel and Lodging | $1,491.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $4,952.06 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $418.52 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $305.38 | 2024-2025 | Total30, Precision7 |
| Sun Pharmaceutical Industries INC. | $250.00 | 2024-2025 | |
| Biotissue Holdings INC. | $194.84 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $167.02 | 2022-2024 | Vyzulta, Infuse |
| Sight Sciences, INC. | $140.00 | 2023 | Tearcare System |
| Coopersurgical, INC. | $134.64 | 2021 | |
| Dompe US, INC. | $122.19 | 2025 | Oxervate |
| Alexion Pharmaceuticals, INC. | $100.07 | 2023 | Soliris |
| Amgen INC. | $83.61 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $66.37 | 2021 | |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.